{
    "organizations": [],
    "uuid": "b4300074eb487ee76a2ff0d394dc7a42f6ec66d0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-clovis-oncology-announces-notice-o/brief-clovis-oncology-announces-notice-of-allowance-for-rucaparib-high-dosage-strength-tablet-patent-with-expiration-in-2035-idUSFWN1QQ0UK",
    "ord_in_thread": 0,
    "title": "BRIEF-Clovis Oncology Announces Notice Of Allowance For Rucaparib High Dosage Strength Tablet Patent With Expiration In 2035",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8 (Reuters) - Clovis Oncology Inc:\n* CLOVIS ONCOLOGY ANNOUNCES NOTICE OF ALLOWANCE FOR RUCAPARIB HIGH DOSAGE STRENGTH TABLET PATENT WITH EXPIRATION IN 2035 Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-03-08T21:11:00.000+02:00",
    "crawled": "2018-03-09T14:43:35.053+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "clovis",
        "oncology",
        "inc",
        "clovis",
        "oncology",
        "announces",
        "notice",
        "allowance",
        "rucaparib",
        "high",
        "dosage",
        "strength",
        "tablet",
        "patent",
        "expiration",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}